Pediatric Studies Of Clolar, Neulasta, Kepivance To Be Discussed By Oncology Subcommittee
This article was originally published in The Pink Sheet Daily
Genzyme and Amgen will share their challenges in design and implementation of post-marketing pediatric studies, such as patient accrual problems and changes in standard of care, at FDA's Oncologic Drugs Advisory Committee on Oct. 20.
You may also be interested in...
Genzyme Clolar Confirmatory Pediatric Study Should Enroll Early Relapse Leukemia Patients, Cmte. Says
Focus on earlier stage disease would enlarge potential pediatric population for study. FDA’s Oncology Pediatric Subcommittee also recommends that primary trial endpoints include remission induction rate.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue